Clinical TrialOct 23, 2026, 11:01 AM
Perspective Therapeutics: [212Pb]VMT-α-NET Shows 50% ORR in NET Trial
AI Summary
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors. The data, presented at ESMO 2026, showed encouraging safety and efficacy, including objective response rates of 33% and 50% in dose cohorts 2 and 3, respectively, and 72% progression-free survival at 18 months. The company is preparing for Phase 3 trial initiation in 2027.
Key Highlights
- Phase 1/2a trial of [212Pb]VMT-α-NET shows 33% ORR in Cohort 2 (5.0 mCi) and 50% ORR in Cohort 3 (6.0 mCi).
- Durable disease control observed, with 72% PFS at 18 months across all treated patients.
- No dose-limiting toxicities (DLTs) or adverse event-related treatment discontinuations reported.
- 29% of patients experienced Grade 3 treatment-emergent adverse events (TEAEs).
- Phase 3 site start-up preparations targeted for year-end 2026, with Phase 3 initiation expected in 2027.
- Additional data to be presented at NANETS 2026 and EORTC-NCI-AACR (ENA) Symposium.
Price Impact
More from CATX